Market Overview:
The global urothelial carcinoma diagnostics market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of urothelial carcinoma, rising demand for early diagnosis and treatment, and technological advancements in diagnostic equipment and reagents and kits. However, the high cost of diagnostic tests is expected to restrain the growth of this market during the forecast period. On the basis of type, the global urothelial carcinoma diagnostics market is segmented into diagnostic equipment, reagents and kits. The diagnostic equipment segment is further sub-segmented into imaging devices (ultrasound scanners, computed tomography scanners), laboratory instruments (spectrophotometers), and other devices (molecular probes). On the basis on application,,the global urothelial carcinoma diagnostics marketis dividedinto contract research organizations(CROs), academic institutions hospitals,,diagnostic centres).
Product Definition:
Urothelial carcinoma diagnostics is the process of detecting and diagnosing urothelial carcinoma, a type of cancer that affects the urinary bladder. Urothelial carcinoma is a relatively rare form of cancer, but it can be deadly if not diagnosed and treated early. Diagnostic tests for urothelial carcinoma include urine tests, cystoscopy, and biopsy.
Diagnostic Equipment:
Urothelial carcinoma is a malignant neoplasm occurring from urothelium. It accounts for 10% of all bladder cancers and is the second most common malignant tumor after non-small cell lung cancer (NSCLC) in patients with bladder cancer. Bladder cancer has a poor prognosis with a survival rate of less than 1 year due to advanced stage at diagnosis, lack of treatment options and high recurrence rates.
Reagents and kits:
Reagents and kits are used for the detection of urinary carcinoma. The reagents and kits can be categorized into two types: those that detect the presence of malignant cells in urine, and those that identify genetic characteristics of cancerous cells.
The increasing prevalence rate of urothelial carcinoma is expected to drive growth during the forecast period.
Application Insights:
The market is segmented by application into contract research organizations, academic institutions, hospitals and diagnostic centers. The contract research organization segment dominated the overall market in terms of revenue share in 2017. This can be attributed to factors such as a high prevalence of cancer coupled with rising demand for faster and accurate diagnosis among other benefits offered by these organizations.
The academic institutions segment is expected to grow at a lucrative rate over the forecast period owing to increasing number of urothelial carcinoma cases across the globe coupled with growing R&D activities pertaining to this disease¢â‚¬â„¢s causes & symptoms. Increasing government funding towards cancer research along with growing awareness about early detection are further anticipated to boost growth over the forecast period.
Urothelial carcinoma is an emerging disease which has led researchers from various institutes worldwide working towards its prevention & control through various studies on its causes & symptoms, screening programs for detecting risk factors associated with it.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a well-established healthcare infrastructure, high adoption of technologically advanced products and increasing government initiatives. Moreover, rising prevalence of urothelial carcinoma is expected to further drive regional growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to factors such as improving healthcare facilities and reimbursement policies favoring early diagnosis coupled with an increase in disposable income levels among patients & their families resulting in higher demand for diagnostic procedures leading towards a rise in revenue generation from 2016 - 2025 in China & Japan respectively. Furthermore, economic development along with improvement in living standards has led towards an increase number of people opting for medical treatments which will also boost regional growth over the next eight years to 2030 UTC).
Growth Factors:
- Increasing incidence of urothelial carcinoma
- Growing demand for early diagnosis and treatment of urothelial carcinoma
- Rising awareness about urothelial carcinoma
- Technological advancements in diagnostic methods for urothelial carcinoma
- Growing number of research studies on urothelial carcinoma
Scope Of The Report
Report Attributes
Report Details
Report Title
Urothelial Carcinoma Diagnostics Market Research Report
By Type
Diagnostic Equipment, Reagents and kits
By Application
Contract Research Organizations, Academic Institutions, Hospitals, Diagnostic Centres
By Companies
Roche Holding, Illumina, IDL Biotech, Agilent Technologies, Olympus, Philips Healthcare, GE Healthcare
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
211
Number of Tables & Figures
148
Customization Available
Yes, the report can be customized as per your need.
Global Urothelial Carcinoma Diagnostics Market Report Segments:
The global Urothelial Carcinoma Diagnostics market is segmented on the basis of:
Types
Diagnostic Equipment, Reagents and kits
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Contract Research Organizations, Academic Institutions, Hospitals, Diagnostic Centres
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche Holding
- Illumina
- IDL Biotech
- Agilent Technologies
- Olympus
- Philips Healthcare
- GE Healthcare
Highlights of The Urothelial Carcinoma Diagnostics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Diagnostic Equipment
- Reagents and kits
- By Application:
- Contract Research Organizations
- Academic Institutions
- Hospitals
- Diagnostic Centres
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Urothelial Carcinoma Diagnostics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Urothelial carcinoma is a type of cancer that develops in the cells that line the urinary tract (urothelium).
Some of the key players operating in the urothelial carcinoma diagnostics market are Roche Holding, Illumina, IDL Biotech, Agilent Technologies, Olympus, Philips Healthcare, GE Healthcare.
The urothelial carcinoma diagnostics market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Urothelial Carcinoma Diagnostics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Urothelial Carcinoma Diagnostics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Urothelial Carcinoma Diagnostics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Urothelial Carcinoma Diagnostics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Urothelial Carcinoma Diagnostics Market Size & Forecast, 2018-2028
4.5.1 Urothelial Carcinoma Diagnostics Market Size and Y-o-Y Growth
4.5.2 Urothelial Carcinoma Diagnostics Market Absolute $ Opportunity
Chapter 5 Global Urothelial Carcinoma Diagnostics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Urothelial Carcinoma Diagnostics Market Size Forecast by Type
5.2.1 Diagnostic Equipment
5.2.2 Reagents and kits
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Urothelial Carcinoma Diagnostics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Urothelial Carcinoma Diagnostics Market Size Forecast by Applications
6.2.1 Contract Research Organizations
6.2.2 Academic Institutions
6.2.3 Hospitals
6.2.4 Diagnostic Centres
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Urothelial Carcinoma Diagnostics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Urothelial Carcinoma Diagnostics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Urothelial Carcinoma Diagnostics Analysis and Forecast
9.1 Introduction
9.2 North America Urothelial Carcinoma Diagnostics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Urothelial Carcinoma Diagnostics Market Size Forecast by Type
9.6.1 Diagnostic Equipment
9.6.2 Reagents and kits
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Urothelial Carcinoma Diagnostics Market Size Forecast by Applications
9.10.1 Contract Research Organizations
9.10.2 Academic Institutions
9.10.3 Hospitals
9.10.4 Diagnostic Centres
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Urothelial Carcinoma Diagnostics Analysis and Forecast
10.1 Introduction
10.2 Europe Urothelial Carcinoma Diagnostics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Urothelial Carcinoma Diagnostics Market Size Forecast by Type
10.6.1 Diagnostic Equipment
10.6.2 Reagents and kits
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Urothelial Carcinoma Diagnostics Market Size Forecast by Applications
10.10.1 Contract Research Organizations
10.10.2 Academic Institutions
10.10.3 Hospitals
10.10.4 Diagnostic Centres
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Urothelial Carcinoma Diagnostics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Urothelial Carcinoma Diagnostics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Urothelial Carcinoma Diagnostics Market Size Forecast by Type
11.6.1 Diagnostic Equipment
11.6.2 Reagents and kits
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Urothelial Carcinoma Diagnostics Market Size Forecast by Applications
11.10.1 Contract Research Organizations
11.10.2 Academic Institutions
11.10.3 Hospitals
11.10.4 Diagnostic Centres
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Urothelial Carcinoma Diagnostics Analysis and Forecast
12.1 Introduction
12.2 Latin America Urothelial Carcinoma Diagnostics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Urothelial Carcinoma Diagnostics Market Size Forecast by Type
12.6.1 Diagnostic Equipment
12.6.2 Reagents and kits
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Urothelial Carcinoma Diagnostics Market Size Forecast by Applications
12.10.1 Contract Research Organizations
12.10.2 Academic Institutions
12.10.3 Hospitals
12.10.4 Diagnostic Centres
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Urothelial Carcinoma Diagnostics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Urothelial Carcinoma Diagnostics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Urothelial Carcinoma Diagnostics Market Size Forecast by Type
13.6.1 Diagnostic Equipment
13.6.2 Reagents and kits
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Urothelial Carcinoma Diagnostics Market Size Forecast by Applications
13.10.1 Contract Research Organizations
13.10.2 Academic Institutions
13.10.3 Hospitals
13.10.4 Diagnostic Centres
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Urothelial Carcinoma Diagnostics Market: Competitive Dashboard
14.2 Global Urothelial Carcinoma Diagnostics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Roche Holding
14.3.2 Illumina
14.3.3 IDL Biotech
14.3.4 Agilent Technologies
14.3.5 Olympus
14.3.6 Philips Healthcare
14.3.7 GE Healthcare
